{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.4","upperLimit":"34.7","value":"11.1"},{"groupId":"OG001","lowerLimit":"16.3","upperLimit":"61.6","value":"36.8"},{"groupId":"OG002","lowerLimit":"24.2","upperLimit":"47.5","value":"35.2"},{"groupId":"OG003","lowerLimit":"21.5","upperLimit":"59.4","value":"39.3"},{"groupId":"OG004","lowerLimit":"10.2","upperLimit":"48.4","value":"26.1"},{"groupId":"OG005","lowerLimit":"1.9","upperLimit":"45.4","value":"15.4"},{"groupId":"OG006","lowerLimit":"34.0","upperLimit":"78.2","value":"57.1"},{"groupId":"OG007","lowerLimit":"14.2","upperLimit":"48.0","value":"29.0"},{"groupId":"OG008","lowerLimit":"36.0","upperLimit":"55.7","value":"45.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"71"},{"groupId":"OG003","value":"28"},{"groupId":"OG004","value":"23"},{"groupId":"OG005","value":"13"},{"groupId":"OG006","value":"21"},{"groupId":"OG007","value":"31"},{"groupId":"OG008","value":"105"}],"units":"Participants"}],"description":"Clinical Benefit Rate was defined as Overall Response Rate or Stable Disease lasting over four months (SD ≥ 4 months)","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with Pathologically proven diagnosis of biliary tract carcinoma","id":"OG000","title":"Biliary Tract Carcinoma Cohort"},{"description":"Patients with pathologically proven diagnosis of carcinoma of unknown primary site","id":"OG001","title":"Carcinoma of Unknown Primary Site Cohort"},{"description":"Patients with pathologically proven diagnosis of endometrial carcinoma","id":"OG002","title":"Endometrial Carcinoma Cohort"},{"description":"Patients with pathologically proven diagnosis of Ewing's Family of Tumors","id":"OG003","title":"Ewing's Family of Tumors Cohort"},{"description":"Patients with pathologically proven diagnosis of Germ Cell Tumors, excluding immature teratoma, or teratoma with malignant transformation.","id":"OG004","title":"Germ Cell Tumors Cohort"},{"description":"Patients with Pathologically proven diagnosis of Head and Neck Carcinoma. Salivary glands tumors were excluded.","id":"OG005","title":"Head and Neck Carcinoma Cohort"},{"description":"Patients with pathologically proven diagnosis of BRCA1/2-associated metastatic breast carcinoma","id":"OG006","title":"BRCA1/2-associated Metastatic Breast Carcinoma Cohort"},{"description":"Patients with Pathologically proven diagnosis of Neuroendocrine Tumors, grade 2 and 3 according to World Health Organization (WHO) classification.","id":"OG007","title":"Neuroendocrine Tumors Cohort"},{"description":"Patients with pathologically proven diagnosis of small cell lung cancer","id":"OG008","title":"Small Cell Lung Cancer Cohort"}],"paramType":"NUMBER","populationDescription":"Treated patients with disease measurement","reportingStatus":"POSTED","timeFrame":"From the start of treatment to the date of progression or the start of a subsequent therapy or end of patient's follow-up, until Cycle 6 (21-day cycle)","title":"Clinical Benefit","type":"SECONDARY","unitOfMeasure":"percentage of participants"}